Catalent Pharma Solutions has entered into a collaboration with Valerion Therapeutics to develop two of Valerion’s lead product candidates to treat orphan genetic diseases. The collaboration will focus on the delivery of muscle-protein fusions, and treatment of multiple indications, in the fields of muscular dystrophies, glycogen storage diseases, myopathies and enzyme-deficiency disorders.   Catalent will provide all cell line engineering, process development and cGMP biomanufacturing for the p...